首页 | 本学科首页   官方微博 | 高级检索  
     


Phase 2 and biomarker study of trebananib,an angiopoietin‐blocking peptibody,with and without bevacizumab for patients with recurrent glioblastoma
Authors:David A. Reardon MD  Andrew B. Lassman MD  David Schiff MD  Shakeeb A. Yunus MD  Elizabeth R. Gerstner MD  Timothy F. Cloughesy MD  Eudocia Quant Lee MD  MPH  Sarah C. Gaffey BS  Jennifer Barrs BS  Jennifer Bruno BS  Alona Muzikansky MA  Daniel G. Duda PhD  DMD  Rakesh K. Jain PhD  Patrick Y. Wen MD
Affiliation:1. Center for Neuro‐Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts;2. Department of Neurology, Columbia University Medical Center, New York, New York;3. Department of Neurology, University of Virginia Medical Center, Charlottesville, Virginia;4. Hematology/Oncology, University of Massachusetts Memorial Medical Center, Worchester, Massachusetts;5. Department of Neuro‐Oncology, Massachusetts General Hospital, Boston, Massachusetts;6. Department of Neurology, University of California, Los Angeles, Los Angeles, California;7. Biostatistics, Massachusetts General Hospital, Boston, Massachusetts;8. Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
Abstract:
Keywords:angiogenesis  angiopoietin  glioblastoma  phase 2  vascular endothelial growth factor (VEGF)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号